5:23 PM ET
8-K
Clinical Trial Data
Opus Genetics Clinical Trial Data
Opus Genetics presented positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. OPGx-BEST1 showed improved retinal sensitivity in 75% of Cohort 1 participants, while OPGx-LCA5 demonstrated sustained visual improvements through 24 months in adults and 6 months in pediatric patients.